z-logo
open-access-imgOpen Access
Preeclampsia 2012
Author(s) -
Elosha Eiland,
Chike Nzerue,
Marquetta Faulkner
Publication year - 2012
Publication title -
journal of pregnancy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.828
H-Index - 32
eISSN - 2090-2735
pISSN - 2090-2727
DOI - 10.1155/2012/586578
Subject(s) - medicine , preeclampsia , intrauterine growth restriction , pathogenesis , disease , pregnancy , hypoxia (environmental) , bioinformatics , fetus , chemistry , genetics , organic chemistry , oxygen , biology
Preeclampsia is a common complication of pregnancy associated with high maternal morbidity and mortality and intrauterine fetal growth restriction. There is extensive evidence that the reduction of uteroplacental blood flow in this syndrome results from the toxic combination of hypoxia, imbalance of angiogenic and antiangiogenic factors, inflammation, and deranged immunity. Women treated for preeclampsia also have an increased risk for cardiovascular and renal disease. At present it is unclear if the increased cardiovascular and renal disease risks are due to residual and or progressive effects of endothelial damage from the preeclampsia or from shared risk factors between preeclampsia and cardiac disease. Moreover, it appears that endothelin-1 signaling may play a central role in the hypertension associated with preeclampsia. In this paper, we discuss emerging data on the pathogenesis of preeclampsia and review therapeutic options.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom